UCSF Neurological Surgery faculty since 1985
 
Director of the Department's Translational Research Program, Dr. Prados has over 20 years' experience at UCSF in treating and supervising the treatment of both adults and children who have brain tumors. The National Cancer Institute's North American Brain Tumor Consortium, which sponsors trials of treatment regimens for brain tumors, is based at UCSF under Dr. Prados' leadership, and he is principal investigator of the Pediatric Brain Tumor Consortium site at UCSF, which is one of 10 institutions in the United States selected to participate in this NIH-funded cooperative effort to develop effective new strategies for treating children with malignant brain tumors.
 
Dr. Prados, both individually and in conjunction with multi-center and multidisciplinary clinical research efforts, supervises and participates in conducting extensive trials of clinical therapy for malignant brain tumors. He is the supervising preceptor training BTRC clinical fellows in conducting clinical trials and analyzing and interpreting clinical trial data. His research interest is in clinical research trials for primary brain tumors. Dr. Prados has been a principal investigator, co-investigator, or collaborating investigator in over 35 research protocols from the National Institutes of Health (NIH), UCSF, and Industry studies over the last several years, and currently is principal investigator or co-investigator of 4 active NIH grants.
 
 
Education, Training, and Previous Positions
 
1970: BS, University of New Orleans
1974; MD, Louisiana State University (LSU) School of Medicine
1974-1975: Internship in Medicine, Charity Hospital in New Orleans
1975-1977: Residency in Internal Medicine, LSU Earl K Long Hospital
1977-1978: Instructor, Internal Medicine, LSU School of Medicine
1979-1982: Assistant Professor, Internal Medicine, LSU School of Medicine
1983: Fellowship in Pulmonary Medicine, Tulane School of Medicine
1984-1985: Assistant Clinical Director of Pulmonary Medicine, Touro Hospital, Tulane University School of Medicine
1985-1987: Fellowship in Neuro-Oncology, University of California San Francisco
1985-1987: Clinical Instructor of Neurosurgery/Neuro-Oncology, Department of Neurological Surgery, UCSF
1987-1989: Acting Director of the UCSF Neuro-Oncology Service
1988-1991: Assistant Clinical Professor, Department of Neurological Surgery, UCSF
1989-present: Director of the UCSF Neuro-Oncology Service
1991-1995: Associate Professor in Residence Neurological Surgery, UCSF
1995-present: Professor in Residence, Neurological Surgery, UCSF
 
Selected Professional Memberships and Appointments
 
American College of Physicians
American Society of Clinical Oncology
Children's Oncology Group
Associate editor, editorial reviewer: Journal of Neuro-Oncology
Associate editor, editorial reviewer: Neuro-Oncology
 
Selected Honors and Awards
 
1976-1977: Chief Resident, Internal Medicine, LSU, E.K. Long Hospital
1985-1987: Clinical Fellow, American Cancer Society
1997: Clinical Excellence Award, Society of Neuro-Oncology
1995-1997: Vice President, Society of Neuro-Oncology
2004-2006: President, Society of Neuro-Oncology
 
Contact
 
Michael D. Prados MD, FACP
University of California, San Francisco
Department of Neurological Surgery
400 Parnassus Av., Room A808
San Francisco, CA 94143-00350
Phone: (415) 353-2383 (academic)
             (415) 353-2408 (clinical)
 
Selected Recent Publications
 
Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 2007; [Epub ahead of print].
 
Chen AM, Chang S, Pouliot J, Sneed PK, Prados MD, Lamborn KR, Malec MK, McDermott MW, Berger MS, Larson DA. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2007;69(3):825-30.
 
Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, Deangelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; for the North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007;13(24):7401-6
 
Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res 2007;13(23):7133-8.
 
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25(16):2288-94.
 
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25(7):837-44.
 
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81(3):271-7.
 
Butowski N, Lamborn KR, Berger MS, Prados MD, Chang SM. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol 2007;85(1):87-94.
 
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 2006;8(1):67-78.
 
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006;24(22):3651-6.
 
Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Puri RK, Chang SM. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005;102(2):267-75.
 
Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, Berger MS, Chang SM. Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 2005;102(4):622-28.
 
Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowtiz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 2005;23(3):525-31.